Nihon Kohden (OTCMKTS:NHNKY) versus Nuwellis (NASDAQ:NUWE) Head to Head Contrast

Nihon Kohden (OTCMKTS:NHNKY) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Valuation & Earnings

This table compares Nihon Kohden and Nuwellis”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nihon Kohden	$1.48 billion	1.33	$93.05 million	$0.51	22.51
Nuwellis	$8.74 million	0.39	-$11.16 million	($107.91)	-0.02

Nihon Kohden has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Nihon Kohden, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

0.1% of Nihon Kohden shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 20.1% of Nuwellis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Nihon Kohden and Nuwellis, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nihon Kohden	0	0	0	1	4.00
Nuwellis	1	0	1	0	2.00

Profitability

This table compares Nihon Kohden and Nuwellis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nihon Kohden	5.32%	7.25%	5.12%
Nuwellis	-202.83%	-1,367.63%	-202.97%

Volatility & Risk

Nihon Kohden has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500.

Summary

Nihon Kohden beats Nuwellis on 11 of the 14 factors compared between the two stocks.

About Nihon Kohden

Nihon Kohden Corporation engages in development, manufacturing, sale, maintenance, and consultation of medical electronic equipment, and related systems and products in Japan, Americas, Europe, rest of Asia, and internationally. It offers physiological measuring equipment comprising electrocardiographs, electroencephalographs, and polygraphs for Cath-labs; patient monitoring systems, such as beside and central monitors; and treatment equipment including defibrillators, automated external defibrillators, ventilators, and pacemakers. The company also provides medical support system, which includes diagnostic and clinical information system; and in-vitro diagnostic equipment comprising hematology and clinical chemistry analyzers. In addition, it operates insurance brokerage and technology licensing business. The company was incorporated in 1951 and is headquartered in Shinjuku, Japan.

About Nuwellis

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.